Last reviewed · How we verify
AK130
At a glance
| Generic name | AK130 |
|---|---|
| Sponsor | Akeso |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC) (PHASE1, PHASE2)
- A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer (PHASE2)
- A Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer (PHASE1, PHASE2)
- A Study of AK130 in Patients With Advanced Malignant Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AK130 CI brief — competitive landscape report
- AK130 updates RSS · CI watch RSS
- Akeso portfolio CI